Gastroparesis Drugs Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Gastroparesis Drugs market size was valued at USD 5822.8 million in 2022 and is forecast to a readjusted size of USD 7722 million by 2029 with a CAGR of 4.1% during review period.

Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.

North America is the largest consumer of Gastroparesis Drugs in global market.The second place is Europe, following North America. Market is not concentrated. Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva and Johnson & Johnsonare the leaders of the industry, and hold the key technologies and patent, with high-end customers.

This report is a detailed and comprehensive analysis for global Gastroparesis Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Gastroparesis Drugs market size and forecasts, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/mg), 2018-2029
Global Gastroparesis Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/mg), 2018-2029
Global Gastroparesis Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/mg), 2018-2029
Global Gastroparesis Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (Kg), and ASP (US$/mg), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gastroparesis Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Gastroparesis Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Sumitomo
   Cadila Pharmaceuticals
   Sanofi
   Teva
   Johnson & Johnson
   Pfizer
   Kyowa Kirin Pharmaceuticals
   Hanmi Pharm
   Ani Pharmaceuticals

   Prokinetic Agents
   Antiemetic Agents
   Others

   Diabetic Gastroparesis
   Idiopathic Gastroparesis

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the Gastroparesis drugs market in 2025?

The increasing prevalence of gastroparesis, especially in diabetic patients, drives the demand for effective treatments. Advancements in drug formulations, combined with growing awareness and improved diagnostic methods, make newer therapies more accessible. The market also benefits from expanding clinical trials and increasing FDA approvals for gastroparesis drugs.

What are the weaknesses of the Gastroparesis drugs market in 2025?

Limited awareness among healthcare professionals and patients regarding the condition hampers early diagnosis and treatment. The lack of a standardized treatment protocol or a "one-size-fits-all" drug leaves patients with limited options. Additionally, some treatments come with side effects, which may discourage patient adherence.

What opportunities exist for the Gastroparesis drugs market in 2025?

There is significant opportunity for innovation in drug development, especially for targeted therapies and personalized medicine. Emerging biologics and gene therapy offer potential breakthroughs. Additionally, collaborations between pharmaceutical companies and research institutions can lead to faster advancements and more effective treatments.

What are the threats to the Gastroparesis drugs market in 2025?

Rising drug costs and reimbursement challenges could limit market growth. Regulatory hurdles for new treatments, along with safety concerns related to long-term use of certain drugs, pose significant threats. Competition from alternative therapies, such as lifestyle modifications or natural treatments, could also affect market dynamics.

What are the political factors affecting the Gastroparesis drugs market in 2025?

Government healthcare policies, including insurance coverage and drug pricing regulations, play a significant role in shaping the market. Political stability in key markets influences the ability to launch new drugs, while regulatory requirements and approval processes impact the pace of innovation.

What are the economic factors affecting the Gastroparesis drugs market in 2025?

Economic conditions such as healthcare budgets and the purchasing power of consumers affect the affordability of gastroparesis treatments. Rising healthcare costs and reimbursement issues can create barriers to access, particularly in low-income populations. On the other hand, economic growth may lead to greater investment in research and development.

What are the social factors affecting the Gastroparesis drugs market in 2025?

Increasing awareness about chronic gastrointestinal conditions and rising health consciousness among populations can drive demand for effective treatments. Social attitudes toward healthcare and treatment adherence also influence how patients engage with new drugs. Additionally, the growing aging population increases the incidence of gastroparesis, creating a larger patient base.

What are the technological factors affecting the Gastroparesis drugs market in 2025?

Advancements in drug development technology, including biotechnology and personalized medicine, hold the potential to revolutionize treatment options. Innovations in diagnostic tools enable earlier detection, which could expand the patient population for targeted therapies. Technology also facilitates the development of more efficient and safer drugs with fewer side effects.

What are the environmental factors affecting the Gastroparesis drugs market in 2025?

Environmental concerns, such as sustainable manufacturing practices and eco-friendly packaging, influence pharmaceutical production. Moreover, environmental factors can impact the distribution and supply chains of drugs. Additionally, climate change may lead to shifts in disease prevalence, indirectly affecting the demand for gastroparesis treatments.

What are the legal factors affecting the Gastroparesis drugs market in 2025?

Stringent regulations governing drug approvals, intellectual property rights, and patent laws affect market entry and competition. Legal challenges related to drug safety, efficacy claims, and liability could slow down the release of new therapies. Ongoing changes in drug approval processes and clinical trial requirements may also shape the regulatory landscape.

Who are the suppliers in the Gastroparesis drugs market in 2025?

Suppliers include pharmaceutical manufacturers, biotechnology companies, research institutions, and raw material suppliers for drug development. Additionally, suppliers of diagnostic equipment and technology providers for drug delivery systems are key contributors to the supply chain.

What are the inputs in the Gastroparesis drugs market in 2025?

Inputs include research and development resources, clinical trial data, regulatory approval processes, raw materials for drug production, and medical expertise. Additionally, patient data, market research, and healthcare infrastructure contribute to the development of new treatments.

What are the processes involved in the Gastroparesis drugs market in 2025?

Key processes include drug discovery, preclinical and clinical trials, regulatory approvals, manufacturing, and distribution. After approval, post-market surveillance and patient education are also crucial to ensure treatment effectiveness and safety.

Who are the customers in the Gastroparesis drugs market in 2025?

Customers include healthcare providers, such as doctors, hospitals, and clinics, who prescribe and administer gastroparesis treatments. Patients suffering from gastroparesis, particularly those with diabetes, are the end users. Insurance companies also play a role in determining treatment accessibility.

What are the outputs in the Gastroparesis drugs market in 2025?

Outputs include approved gastroparesis drugs, improved patient outcomes, and market expansion of innovative treatments. Additionally, educational materials and healthcare solutions for managing gastroparesis contribute to the overall output in the market.

What is the threat of new entrants in the Gastroparesis drugs market in 2025?

The threat of new entrants is moderate due to high barriers to entry, including the cost and time required for drug development, regulatory approvals, and clinical trials. Established pharmaceutical companies with strong pipelines and market recognition dominate, making it difficult for new players to break into the market.

What is the bargaining power of suppliers in the Gastroparesis drugs market in 2025?

The bargaining power of suppliers is relatively moderate. While pharmaceutical companies depend on suppliers for raw materials and technology, the market is not highly concentrated, allowing manufacturers some flexibility in sourcing. However, specialized raw materials for advanced drug formulations can give certain suppliers more leverage.

What is the bargaining power of buyers in the Gastroparesis drugs market in 2025?

The bargaining power of buyers is low to moderate. Patients and healthcare providers have limited power over drug pricing, especially in a specialized field like gastroparesis, where treatment options are scarce. However, insurance companies and healthcare providers can influence pricing and treatment decisions through coverage policies.

What is the threat of substitute products in the Gastroparesis drugs market in 2025?

The threat of substitutes is moderate. While there are limited direct substitutes for gastroparesis drugs, lifestyle changes, dietary adjustments, and natural remedies may offer alternatives for some patients. However, these substitutes generally don’t offer the same level of clinical efficacy, which keeps the demand for prescription drugs strong.

What is the intensity of competitive rivalry in the Gastroparesis drugs market in 2025?

The intensity of competitive rivalry is moderate. The market is still evolving, with a few key players focusing on research and innovation. However, competition is increasing as more companies invest in the development of effective treatments, leading to a race to bring new, improved drugs to market.

What are the key raw materials and components involved in the Gastroparesis drugs market in 2025?

Key raw materials include active pharmaceutical ingredients (APIs), excipients, and biotechnological components necessary for drug formulation. In addition, packaging materials and specialized drug delivery systems (like injectables or slow-release formulations) are crucial components in the production process.

What role do suppliers play in the Gastroparesis drugs market in 2025?

Suppliers provide the essential raw materials, technologies, and equipment needed for the development and manufacturing of gastroparesis drugs. They play a critical role in ensuring quality control, timely delivery of materials, and maintaining the stability of production cycles for pharmaceutical companies.

What are the challenges in the upstream part of the Gastroparesis drugs market in 2025?

Challenges include the high cost of raw materials, the need for specialized production capabilities, and ensuring the availability of high-quality APIs. Regulatory requirements and compliance with manufacturing standards add complexity. Additionally, dependency on a few suppliers for specific components increases vulnerability in the supply chain.

How does innovation affect the upstream segment of the Gastroparesis drugs market in 2025?

Innovation drives the development of new drug formulations, such as biologics or personalized medicine, which require advanced technologies and unique raw materials. This leads to higher demand for cutting-edge research and specialized suppliers, influencing both cost and production timelines.

What is the impact of regulatory requirements on the upstream segment in the Gastroparesis drugs market in 2025?

Regulatory requirements significantly influence the upstream market by ensuring the safety, efficacy, and quality of raw materials used in drug manufacturing. Compliance with stringent standards for manufacturing, labeling, and packaging increases production complexity and costs, but it is essential to maintain market access and patient safety.

What are the key processes in the midstream segment of the Gastroparesis drugs market in 2025?

The key processes in the midstream segment include drug formulation, clinical trials, regulatory approvals, and manufacturing. These steps are critical for ensuring the safety, efficacy, and commercial viability of gastroparesis treatments. Clinical trials and FDA approval are particularly vital for moving drugs from research to market.

How do manufacturers influence the midstream segment of the Gastroparesis drugs market in 2025?

Manufacturers are responsible for producing drugs at scale, ensuring they meet regulatory standards, and managing supply chain logistics. Their role in efficient production and distribution impacts both the availability and affordability of gastroparesis treatments. Additionally, innovation in drug delivery methods and dosage forms plays a significant role in market success.

What challenges exist in the midstream segment of the Gastroparesis drugs market in 2025?

Challenges include navigating the complexities of clinical trials, managing regulatory hurdles, and the high costs associated with manufacturing and scaling production. Additionally, maintaining consistent drug quality, dealing with supply chain disruptions, and addressing patient-specific treatment needs add to the operational complexity.

How does innovation impact the midstream segment of the Gastroparesis drugs market in 2025?

Innovation drives the development of more effective drug formulations and delivery methods. New technologies, such as biologics or advanced drug-release systems, can improve treatment outcomes, but they often require specialized manufacturing processes and higher investment in research and development.

What role do clinical trials play in the midstream segment of the Gastroparesis drugs market in 2025?

Clinical trials are crucial in testing the safety and efficacy of new gastroparesis drugs. They provide the data needed for regulatory approval and guide the development of treatment protocols. Successful trials also pave the way for market entry, making them a key element in the midstream process.

What are the key distribution channels in the Gastroparesis drugs market in 2025?

Key distribution channels include pharmacies, hospitals, healthcare providers, and specialty clinics. These channels play a critical role in delivering gastroparesis medications directly to patients. Additionally, online platforms for ordering prescriptions may become more common as e-health trends grow.

How do healthcare providers impact the downstream segment of the Gastroparesis drugs market in 2025?

Healthcare providers, including doctors, specialists, and dietitians, influence the downstream market by diagnosing patients and prescribing the appropriate treatments. Their decisions are based on the efficacy, safety, and patient-specific needs, thus directly affecting drug usage patterns and market dynamics.

What challenges exist in the downstream segment of the Gastroparesis drugs market in 2025?

Challenges include ensuring patient access to treatments, especially in areas with limited healthcare resources. Pricing and reimbursement issues, especially for newer or biologic therapies, can restrict patient access. Additionally, healthcare provider education about emerging treatments and patient adherence to prescribed regimens remain key concerns.

How does patient education influence the downstream segment of the Gastroparesis drugs market in 2025?

Patient education is essential for ensuring that individuals suffering from gastroparesis understand their condition and the importance of following treatment protocols. Well-educated patients are more likely to adhere to treatment regimens, leading to better outcomes and sustained demand for drugs.

What is the role of insurance companies in the downstream segment of the Gastroparesis drugs market in 2025?

Insurance companies play a significant role by determining coverage for gastroparesis drugs and influencing treatment choices through reimbursement policies. Their decisions impact which drugs are accessible to patients, and this affects drug uptake and market penetration.

Chapter 1, to describe Gastroparesis Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gastroparesis Drugs, with price, sales, revenue and global market share of Gastroparesis Drugs from 2018 to 2023.
Chapter 3, the Gastroparesis Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gastroparesis Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Gastroparesis Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gastroparesis Drugs.
Chapter 14 and 15, to describe Gastroparesis Drugs sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Gastroparesis Drugs
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Type
       1.3.1 Overview: Global Gastroparesis Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Prokinetic Agents
       1.3.3 Antiemetic Agents
       1.3.4 Others
   1.4 Market Analysis by Application
       1.4.1 Overview: Global Gastroparesis Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Diabetic Gastroparesis
       1.4.3 Idiopathic Gastroparesis
   1.5 Global Gastroparesis Drugs Market Size & Forecast
       1.5.1 Global Gastroparesis Drugs Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global Gastroparesis Drugs Sales Quantity (2018-2029)
       1.5.3 Global Gastroparesis Drugs Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 Sumitomo
       2.1.1 Sumitomo Details
       2.1.2 Sumitomo Major Business
       2.1.3 Sumitomo Gastroparesis Drugs Product and Services
       2.1.4 Sumitomo Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Sumitomo Recent Developments/Updates
   2.2 Cadila Pharmaceuticals
       2.2.1 Cadila Pharmaceuticals Details
       2.2.2 Cadila Pharmaceuticals Major Business
       2.2.3 Cadila Pharmaceuticals Gastroparesis Drugs Product and Services
       2.2.4 Cadila Pharmaceuticals Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Cadila Pharmaceuticals Recent Developments/Updates
   2.3 Sanofi
       2.3.1 Sanofi Details
       2.3.2 Sanofi Major Business
       2.3.3 Sanofi Gastroparesis Drugs Product and Services
       2.3.4 Sanofi Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Sanofi Recent Developments/Updates
   2.4 Teva
       2.4.1 Teva Details
       2.4.2 Teva Major Business
       2.4.3 Teva Gastroparesis Drugs Product and Services
       2.4.4 Teva Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Teva Recent Developments/Updates
   2.5 Johnson & Johnson
       2.5.1 Johnson & Johnson Details
       2.5.2 Johnson & Johnson Major Business
       2.5.3 Johnson & Johnson Gastroparesis Drugs Product and Services
       2.5.4 Johnson & Johnson Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Johnson & Johnson Recent Developments/Updates
   2.6 Pfizer
       2.6.1 Pfizer Details
       2.6.2 Pfizer Major Business
       2.6.3 Pfizer Gastroparesis Drugs Product and Services
       2.6.4 Pfizer Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Pfizer Recent Developments/Updates
   2.7 Kyowa Kirin Pharmaceuticals
       2.7.1 Kyowa Kirin Pharmaceuticals Details
       2.7.2 Kyowa Kirin Pharmaceuticals Major Business
       2.7.3 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Product and Services
       2.7.4 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Kyowa Kirin Pharmaceuticals Recent Developments/Updates
   2.8 Hanmi Pharm
       2.8.1 Hanmi Pharm Details
       2.8.2 Hanmi Pharm Major Business
       2.8.3 Hanmi Pharm Gastroparesis Drugs Product and Services
       2.8.4 Hanmi Pharm Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Hanmi Pharm Recent Developments/Updates
   2.9 Ani Pharmaceuticals
       2.9.1 Ani Pharmaceuticals Details
       2.9.2 Ani Pharmaceuticals Major Business
       2.9.3 Ani Pharmaceuticals Gastroparesis Drugs Product and Services
       2.9.4 Ani Pharmaceuticals Gastroparesis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 Ani Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Gastroparesis Drugs by Manufacturer

   3.1 Global Gastroparesis Drugs Sales Quantity by Manufacturer (2018-2023)
   3.2 Global Gastroparesis Drugs Revenue by Manufacturer (2018-2023)
   3.3 Global Gastroparesis Drugs Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of Gastroparesis Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 Gastroparesis Drugs Manufacturer Market Share in 2022
       3.4.2 Top 6 Gastroparesis Drugs Manufacturer Market Share in 2022
   3.5 Gastroparesis Drugs Market: Overall Company Footprint Analysis
       3.5.1 Gastroparesis Drugs Market: Region Footprint
       3.5.2 Gastroparesis Drugs Market: Company Product Type Footprint
       3.5.3 Gastroparesis Drugs Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global Gastroparesis Drugs Market Size by Region
       4.1.1 Global Gastroparesis Drugs Sales Quantity by Region (2018-2029)
       4.1.2 Global Gastroparesis Drugs Consumption Value by Region (2018-2029)
       4.1.3 Global Gastroparesis Drugs Average Price by Region (2018-2029)
   4.2 North America Gastroparesis Drugs Consumption Value (2018-2029)
   4.3 Europe Gastroparesis Drugs Consumption Value (2018-2029)
   4.4 Asia-Pacific Gastroparesis Drugs Consumption Value (2018-2029)
   4.5 South America Gastroparesis Drugs Consumption Value (2018-2029)
   4.6 Middle East and Africa Gastroparesis Drugs Consumption Value (2018-2029)

5 Market Segment by Type

   5.1 Global Gastroparesis Drugs Sales Quantity by Type (2018-2029)
   5.2 Global Gastroparesis Drugs Consumption Value by Type (2018-2029)
   5.3 Global Gastroparesis Drugs Average Price by Type (2018-2029)

6 Market Segment by Application

   6.1 Global Gastroparesis Drugs Sales Quantity by Application (2018-2029)
   6.2 Global Gastroparesis Drugs Consumption Value by Application (2018-2029)
   6.3 Global Gastroparesis Drugs Average Price by Application (2018-2029)

7 North America

   7.1 North America Gastroparesis Drugs Sales Quantity by Type (2018-2029)
   7.2 North America Gastroparesis Drugs Sales Quantity by Application (2018-2029)
   7.3 North America Gastroparesis Drugs Market Size by Country
       7.3.1 North America Gastroparesis Drugs Sales Quantity by Country (2018-2029)
       7.3.2 North America Gastroparesis Drugs Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe Gastroparesis Drugs Sales Quantity by Type (2018-2029)
   8.2 Europe Gastroparesis Drugs Sales Quantity by Application (2018-2029)
   8.3 Europe Gastroparesis Drugs Market Size by Country
       8.3.1 Europe Gastroparesis Drugs Sales Quantity by Country (2018-2029)
       8.3.2 Europe Gastroparesis Drugs Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific Gastroparesis Drugs Sales Quantity by Type (2018-2029)
   9.2 Asia-Pacific Gastroparesis Drugs Sales Quantity by Application (2018-2029)
   9.3 Asia-Pacific Gastroparesis Drugs Market Size by Region
       9.3.1 Asia-Pacific Gastroparesis Drugs Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific Gastroparesis Drugs Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America Gastroparesis Drugs Sales Quantity by Type (2018-2029)
   10.2 South America Gastroparesis Drugs Sales Quantity by Application (2018-2029)
   10.3 South America Gastroparesis Drugs Market Size by Country
       10.3.1 South America Gastroparesis Drugs Sales Quantity by Country (2018-2029)
       10.3.2 South America Gastroparesis Drugs Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa Gastroparesis Drugs Sales Quantity by Type (2018-2029)
   11.2 Middle East & Africa Gastroparesis Drugs Sales Quantity by Application (2018-2029)
   11.3 Middle East & Africa Gastroparesis Drugs Market Size by Country
       11.3.1 Middle East & Africa Gastroparesis Drugs Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa Gastroparesis Drugs Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 Gastroparesis Drugs Market Drivers
   12.2 Gastroparesis Drugs Market Restraints
   12.3 Gastroparesis Drugs Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry
   12.5 Influence of COVID-19 and Russia-Ukraine War
       12.5.1 Influence of COVID-19
       12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

   13.1 Raw Material of Gastroparesis Drugs and Key Manufacturers
   13.2 Manufacturing Costs Percentage of Gastroparesis Drugs
   13.3 Gastroparesis Drugs Production Process
   13.4 Gastroparesis Drugs Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 Gastroparesis Drugs Typical Distributors
   14.3 Gastroparesis Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global Gastroparesis Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Gastroparesis Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Sumitomo Basic Information, Manufacturing Base and Competitors
   Table 4. Sumitomo Major Business
   Table 5. Sumitomo Gastroparesis Drugs Product and Services
   Table 6. Sumitomo Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. Sumitomo Recent Developments/Updates
   Table 8. Cadila Pharmaceuticals Basic Information, Manufacturing Base and Competitors
   Table 9. Cadila Pharmaceuticals Major Business
   Table 10. Cadila Pharmaceuticals Gastroparesis Drugs Product and Services
   Table 11. Cadila Pharmaceuticals Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 12. Cadila Pharmaceuticals Recent Developments/Updates
   Table 13. Sanofi Basic Information, Manufacturing Base and Competitors
   Table 14. Sanofi Major Business
   Table 15. Sanofi Gastroparesis Drugs Product and Services
   Table 16. Sanofi Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 17. Sanofi Recent Developments/Updates
   Table 18. Teva Basic Information, Manufacturing Base and Competitors
   Table 19. Teva Major Business
   Table 20. Teva Gastroparesis Drugs Product and Services
   Table 21. Teva Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 22. Teva Recent Developments/Updates
   Table 23. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
   Table 24. Johnson & Johnson Major Business
   Table 25. Johnson & Johnson Gastroparesis Drugs Product and Services
   Table 26. Johnson & Johnson Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 27. Johnson & Johnson Recent Developments/Updates
   Table 28. Pfizer Basic Information, Manufacturing Base and Competitors
   Table 29. Pfizer Major Business
   Table 30. Pfizer Gastroparesis Drugs Product and Services
   Table 31. Pfizer Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 32. Pfizer Recent Developments/Updates
   Table 33. Kyowa Kirin Pharmaceuticals Basic Information, Manufacturing Base and Competitors
   Table 34. Kyowa Kirin Pharmaceuticals Major Business
   Table 35. Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Product and Services
   Table 36. Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 37. Kyowa Kirin Pharmaceuticals Recent Developments/Updates
   Table 38. Hanmi Pharm Basic Information, Manufacturing Base and Competitors
   Table 39. Hanmi Pharm Major Business
   Table 40. Hanmi Pharm Gastroparesis Drugs Product and Services
   Table 41. Hanmi Pharm Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 42. Hanmi Pharm Recent Developments/Updates
   Table 43. Ani Pharmaceuticals Basic Information, Manufacturing Base and Competitors
   Table 44. Ani Pharmaceuticals Major Business
   Table 45. Ani Pharmaceuticals Gastroparesis Drugs Product and Services
   Table 46. Ani Pharmaceuticals Gastroparesis Drugs Sales Quantity (Kg), Average Price (US$/mg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 47. Ani Pharmaceuticals Recent Developments/Updates
   Table 48. Global Gastroparesis Drugs Sales Quantity by Manufacturer (2018-2023) & (Kg)
   Table 49. Global Gastroparesis Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 50. Global Gastroparesis Drugs Average Price by Manufacturer (2018-2023) & (US$/mg)
   Table 51. Market Position of Manufacturers in Gastroparesis Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 52. Head Office and Gastroparesis Drugs Production Site of Key Manufacturer
   Table 53. Gastroparesis Drugs Market: Company Product Type Footprint
   Table 54. Gastroparesis Drugs Market: Company Product Application Footprint
   Table 55. Gastroparesis Drugs New Market Entrants and Barriers to Market Entry
   Table 56. Gastroparesis Drugs Mergers, Acquisition, Agreements, and Collaborations
   Table 57. Global Gastroparesis Drugs Sales Quantity by Region (2018-2023) & (Kg)
   Table 58. Global Gastroparesis Drugs Sales Quantity by Region (2024-2029) & (Kg)
   Table 59. Global Gastroparesis Drugs Consumption Value by Region (2018-2023) & (USD Million)
   Table 60. Global Gastroparesis Drugs Consumption Value by Region (2024-2029) & (USD Million)
   Table 61. Global Gastroparesis Drugs Average Price by Region (2018-2023) & (US$/mg)
   Table 62. Global Gastroparesis Drugs Average Price by Region (2024-2029) & (US$/mg)
   Table 63. Global Gastroparesis Drugs Sales Quantity by Type (2018-2023) & (Kg)
   Table 64. Global Gastroparesis Drugs Sales Quantity by Type (2024-2029) & (Kg)
   Table 65. Global Gastroparesis Drugs Consumption Value by Type (2018-2023) & (USD Million)
   Table 66. Global Gastroparesis Drugs Consumption Value by Type (2024-2029) & (USD Million)
   Table 67. Global Gastroparesis Drugs Average Price by Type (2018-2023) & (US$/mg)
   Table 68. Global Gastroparesis Drugs Average Price by Type (2024-2029) & (US$/mg)
   Table 69. Global Gastroparesis Drugs Sales Quantity by Application (2018-2023) & (Kg)
   Table 70. Global Gastroparesis Drugs Sales Quantity by Application (2024-2029) & (Kg)
   Table 71. Global Gastroparesis Drugs Consumption Value by Application (2018-2023) & (USD Million)
   Table 72. Global Gastroparesis Drugs Consumption Value by Application (2024-2029) & (USD Million)
   Table 73. Global Gastroparesis Drugs Average Price by Application (2018-2023) & (US$/mg)
   Table 74. Global Gastroparesis Drugs Average Price by Application (2024-2029) & (US$/mg)
   Table 75. North America Gastroparesis Drugs Sales Quantity by Type (2018-2023) & (Kg)
   Table 76. North America Gastroparesis Drugs Sales Quantity by Type (2024-2029) & (Kg)
   Table 77. North America Gastroparesis Drugs Sales Quantity by Application (2018-2023) & (Kg)
   Table 78. North America Gastroparesis Drugs Sales Quantity by Application (2024-2029) & (Kg)
   Table 79. North America Gastroparesis Drugs Sales Quantity by Country (2018-2023) & (Kg)
   Table 80. North America Gastroparesis Drugs Sales Quantity by Country (2024-2029) & (Kg)
   Table 81. North America Gastroparesis Drugs Consumption Value by Country (2018-2023) & (USD Million)
   Table 82. North America Gastroparesis Drugs Consumption Value by Country (2024-2029) & (USD Million)
   Table 83. Europe Gastroparesis Drugs Sales Quantity by Type (2018-2023) & (Kg)
   Table 84. Europe Gastroparesis Drugs Sales Quantity by Type (2024-2029) & (Kg)
   Table 85. Europe Gastroparesis Drugs Sales Quantity by Application (2018-2023) & (Kg)
   Table 86. Europe Gastroparesis Drugs Sales Quantity by Application (2024-2029) & (Kg)
   Table 87. Europe Gastroparesis Drugs Sales Quantity by Country (2018-2023) & (Kg)
   Table 88. Europe Gastroparesis Drugs Sales Quantity by Country (2024-2029) & (Kg)
   Table 89. Europe Gastroparesis Drugs Consumption Value by Country (2018-2023) & (USD Million)
   Table 90. Europe Gastroparesis Drugs Consumption Value by Country (2024-2029) & (USD Million)
   Table 91. Asia-Pacific Gastroparesis Drugs Sales Quantity by Type (2018-2023) & (Kg)
   Table 92. Asia-Pacific Gastroparesis Drugs Sales Quantity by Type (2024-2029) & (Kg)
   Table 93. Asia-Pacific Gastroparesis Drugs Sales Quantity by Application (2018-2023) & (Kg)
   Table 94. Asia-Pacific Gastroparesis Drugs Sales Quantity by Application (2024-2029) & (Kg)
   Table 95. Asia-Pacific Gastroparesis Drugs Sales Quantity by Region (2018-2023) & (Kg)
   Table 96. Asia-Pacific Gastroparesis Drugs Sales Quantity by Region (2024-2029) & (Kg)
   Table 97. Asia-Pacific Gastroparesis Drugs Consumption Value by Region (2018-2023) & (USD Million)
   Table 98. Asia-Pacific Gastroparesis Drugs Consumption Value by Region (2024-2029) & (USD Million)
   Table 99. South America Gastroparesis Drugs Sales Quantity by Type (2018-2023) & (Kg)
   Table 100. South America Gastroparesis Drugs Sales Quantity by Type (2024-2029) & (Kg)
   Table 101. South America Gastroparesis Drugs Sales Quantity by Application (2018-2023) & (Kg)
   Table 102. South America Gastroparesis Drugs Sales Quantity by Application (2024-2029) & (Kg)
   Table 103. South America Gastroparesis Drugs Sales Quantity by Country (2018-2023) & (Kg)
   Table 104. South America Gastroparesis Drugs Sales Quantity by Country (2024-2029) & (Kg)
   Table 105. South America Gastroparesis Drugs Consumption Value by Country (2018-2023) & (USD Million)
   Table 106. South America Gastroparesis Drugs Consumption Value by Country (2024-2029) & (USD Million)
   Table 107. Middle East & Africa Gastroparesis Drugs Sales Quantity by Type (2018-2023) & (Kg)
   Table 108. Middle East & Africa Gastroparesis Drugs Sales Quantity by Type (2024-2029) & (Kg)
   Table 109. Middle East & Africa Gastroparesis Drugs Sales Quantity by Application (2018-2023) & (Kg)
   Table 110. Middle East & Africa Gastroparesis Drugs Sales Quantity by Application (2024-2029) & (Kg)
   Table 111. Middle East & Africa Gastroparesis Drugs Sales Quantity by Region (2018-2023) & (Kg)
   Table 112. Middle East & Africa Gastroparesis Drugs Sales Quantity by Region (2024-2029) & (Kg)
   Table 113. Middle East & Africa Gastroparesis Drugs Consumption Value by Region (2018-2023) & (USD Million)
   Table 114. Middle East & Africa Gastroparesis Drugs Consumption Value by Region (2024-2029) & (USD Million)
   Table 115. Gastroparesis Drugs Raw Material
   Table 116. Key Manufacturers of Gastroparesis Drugs Raw Materials
   Table 117. Gastroparesis Drugs Typical Distributors
   Table 118. Gastroparesis Drugs Typical Customers

List of Figures

   Figure 1. Gastroparesis Drugs Picture
   Figure 2. Global Gastroparesis Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Gastroparesis Drugs Consumption Value Market Share by Type in 2022
   Figure 4. Prokinetic Agents Examples
   Figure 5. Antiemetic Agents Examples
   Figure 6. Others Examples
   Figure 7. Global Gastroparesis Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Figure 8. Global Gastroparesis Drugs Consumption Value Market Share by Application in 2022
   Figure 9. Diabetic Gastroparesis Examples
   Figure 10. Idiopathic Gastroparesis Examples
   Figure 11. Global Gastroparesis Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global Gastroparesis Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global Gastroparesis Drugs Sales Quantity (2018-2029) & (Kg)
   Figure 14. Global Gastroparesis Drugs Average Price (2018-2029) & (US$/mg)
   Figure 15. Global Gastroparesis Drugs Sales Quantity Market Share by Manufacturer in 2022
   Figure 16. Global Gastroparesis Drugs Consumption Value Market Share by Manufacturer in 2022
   Figure 17. Producer Shipments of Gastroparesis Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 18. Top 3 Gastroparesis Drugs Manufacturer (Consumption Value) Market Share in 2022
   Figure 19. Top 6 Gastroparesis Drugs Manufacturer (Consumption Value) Market Share in 2022
   Figure 20. Global Gastroparesis Drugs Sales Quantity Market Share by Region (2018-2029)
   Figure 21. Global Gastroparesis Drugs Consumption Value Market Share by Region (2018-2029)
   Figure 22. North America Gastroparesis Drugs Consumption Value (2018-2029) & (USD Million)
   Figure 23. Europe Gastroparesis Drugs Consumption Value (2018-2029) & (USD Million)
   Figure 24. Asia-Pacific Gastroparesis Drugs Consumption Value (2018-2029) & (USD Million)
   Figure 25. South America Gastroparesis Drugs Consumption Value (2018-2029) & (USD Million)
   Figure 26. Middle East & Africa Gastroparesis Drugs Consumption Value (2018-2029) & (USD Million)
   Figure 27. Global Gastroparesis Drugs Sales Quantity Market Share by Type (2018-2029)
   Figure 28. Global Gastroparesis Drugs Consumption Value Market Share by Type (2018-2029)
   Figure 29. Global Gastroparesis Drugs Average Price by Type (2018-2029) & (US$/mg)
   Figure 30. Global Gastroparesis Drugs Sales Quantity Market Share by Application (2018-2029)
   Figure 31. Global Gastroparesis Drugs Consumption Value Market Share by Application (2018-2029)
   Figure 32. Global Gastroparesis Drugs Average Price by Application (2018-2029) & (US$/mg)
   Figure 33. North America Gastroparesis Drugs Sales Quantity Market Share by Type (2018-2029)
   Figure 34. North America Gastroparesis Drugs Sales Quantity Market Share by Application (2018-2029)
   Figure 35. North America Gastroparesis Drugs Sales Quantity Market Share by Country (2018-2029)
   Figure 36. North America Gastroparesis Drugs Consumption Value Market Share by Country (2018-2029)
   Figure 37. United States Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 38. Canada Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 39. Mexico Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 40. Europe Gastroparesis Drugs Sales Quantity Market Share by Type (2018-2029)
   Figure 41. Europe Gastroparesis Drugs Sales Quantity Market Share by Application (2018-2029)
   Figure 42. Europe Gastroparesis Drugs Sales Quantity Market Share by Country (2018-2029)
   Figure 43. Europe Gastroparesis Drugs Consumption Value Market Share by Country (2018-2029)
   Figure 44. Germany Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 45. France Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 46. United Kingdom Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 47. Russia Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. Italy Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. Asia-Pacific Gastroparesis Drugs Sales Quantity Market Share by Type (2018-2029)
   Figure 50. Asia-Pacific Gastroparesis Drugs Sales Quantity Market Share by Application (2018-2029)
   Figure 51. Asia-Pacific Gastroparesis Drugs Sales Quantity Market Share by Region (2018-2029)
   Figure 52. Asia-Pacific Gastroparesis Drugs Consumption Value Market Share by Region (2018-2029)
   Figure 53. China Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 54. Japan Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 55. Korea Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 56. India Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. Southeast Asia Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. Australia Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. South America Gastroparesis Drugs Sales Quantity Market Share by Type (2018-2029)
   Figure 60. South America Gastroparesis Drugs Sales Quantity Market Share by Application (2018-2029)
   Figure 61. South America Gastroparesis Drugs Sales Quantity Market Share by Country (2018-2029)
   Figure 62. South America Gastroparesis Drugs Consumption Value Market Share by Country (2018-2029)
   Figure 63. Brazil Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 64. Argentina Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 65. Middle East & Africa Gastroparesis Drugs Sales Quantity Market Share by Type (2018-2029)
   Figure 66. Middle East & Africa Gastroparesis Drugs Sales Quantity Market Share by Application (2018-2029)
   Figure 67. Middle East & Africa Gastroparesis Drugs Sales Quantity Market Share by Region (2018-2029)
   Figure 68. Middle East & Africa Gastroparesis Drugs Consumption Value Market Share by Region (2018-2029)
   Figure 69. Turkey Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 70. Egypt Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 71. Saudi Arabia Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 72. South Africa Gastroparesis Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. Gastroparesis Drugs Market Drivers
   Figure 74. Gastroparesis Drugs Market Restraints
   Figure 75. Gastroparesis Drugs Market Trends
   Figure 76. Porters Five Forces Analysis
   Figure 77. Manufacturing Cost Structure Analysis of Gastroparesis Drugs in 2022
   Figure 78. Manufacturing Process Analysis of Gastroparesis Drugs
   Figure 79. Gastroparesis Drugs Industrial Chain
   Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 81. Direct Channel Pros & Cons
   Figure 82. Indirect Channel Pros & Cons
   Figure 83. Methodology
   Figure 84. Research Process and Data Source